Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study

Lasmiditan is a centrally penetrant, highly selective 5‐hydroxytryptamine (serotonin) receptor 1F (5HT(1F)) agonist under development as a novel therapy for acute treatment of migraine. A phase 1 randomized, placebo‐ and positive‐controlled crossover study assessed the abuse potential of lasmiditan...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Pharmacol
Main Authors: Wilbraham, Darren, Berg, Paul H., Tsai, Max, Liffick, Emily, Loo, Li Shen, Doty, Erin Gautier, Sellers, Edward
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Pharmacodynamics
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7078915/
https://ncbi.nlm.nih.gov/pubmed/31745991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1543
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki